Albany Molecular Res (AMRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2017 | 03-2017 | 12-2016 | 09-2016 | 06-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -20,937 | -10,692 | -70,171 | -54,760 | -31,335 |
| Depreciation Amortization | 38,675 | 18,816 | 56,706 | 35,440 | 18,419 |
| Income taxes - deferred | -6,648 | 290 | 943 | 469 | 9,667 |
| Accounts receivable | 10,169 | 5,892 | -10,787 | 14,127 | 9,886 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | 6,416 | N/A |
| Other Working Capital | -16,763 | -20,824 | 14,966 | 9,915 | 3,674 |
| Other Operating Activity | 4,024 | 108 | 34,978 | -6,379 | 4,930 |
| Operating Cash Flow | $8,520 | $-6,410 | $26,635 | $5,228 | $15,241 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -10,486 | -3,949 | -50,740 | -37,264 | -24,291 |
| Net Acquisitions | N/A | N/A | -142,016 | -144,325 | -1,056 |
| Purchase Sale Intangibles | -151 | -113 | -441 | -188 | -158 |
| Other Investing Activity | -151 | -113 | -441 | -188 | -158 |
| Investing Cash Flow | $-10,637 | $-4,062 | $-193,197 | $-181,777 | $-25,505 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 52,547 | 28,066 | 50,344 | 20,340 | N/A |
| Debt Issued | N/A | N/A | 227,792 | 228,042 | 250 |
| Debt Repayment | -7,352 | -3,965 | -48,961 | -44,881 | -10,773 |
| Common Stock Issued | 921 | 632 | 2,024 | 1,828 | 903 |
| Common Stock Repurchased | -1,951 | -1,883 | -974 | -842 | -770 |
| Other Financing Activity | -56,050 | -30,087 | -59,380 | -32,477 | 2,253 |
| Financing Cash Flow | $-11,885 | $-7,237 | $170,845 | $172,010 | $-8,137 |
| Exchange Rate Effect | 4,229 | 902 | -1,626 | -48 | -267 |
| Beginning Cash Position | 52,000 | 52,000 | 49,343 | 49,343 | 49,343 |
| End Cash Position | 42,227 | 35,193 | 52,000 | 44,756 | 30,675 |
| Net Cash Flow | $-9,773 | $-16,807 | $2,657 | $-4,587 | $-18,668 |
| Free Cash Flow | |||||
| Operating Cash Flow | 8,520 | -6,410 | 26,635 | 5,228 | 15,241 |
| Capital Expenditure | -10,486 | -3,949 | -51,428 | -37,952 | -24,966 |
| Free Cash Flow | -1,966 | -10,359 | -24,793 | -32,724 | -9,725 |